INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

Rhea-AI Summary

INOVIO (NASDAQ: INO), a biotechnology company specializing in DNA medicines, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close.

The company, which focuses on developing treatments for HPV-associated diseases, cancers, and infectious diseases, will host a live conference call and webcast at 4:30 p.m. ET on the same day. The event will include:

• A general business update presentation
• Live Q&A session with analysts
• Webcast access through http://ir.inovio.com/events-and-presentations/default.aspx

The webcast will be available for replay for 90 days following the event. This listen-only event provides investors and stakeholders an opportunity to stay updated on INOVIO's financial performance and business developments.

Positive

• DNA medicines portfolio focused on high-value areas: HPV diseases, cancers, and infectious diseases

Negative

• None.

PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.

The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-report-first-quarter-2025-financial-results-on-may-13-2025-302440001.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

When will INOVIO (INO) release Q1 2025 earnings?

INOVIO (INO) will release its first quarter 2025 financial results on May 13, 2025, after the market close.

How can I listen to INOVIO's Q1 2025 earnings call?

Investors can access INOVIO's Q1 2025 earnings call via live webcast at 4:30 p.m. ET on May 13, 2025, through http://ir.inovio.com/events-and-presentations/default.aspx.

How long will INOVIO's Q1 2025 earnings webcast be available for replay?

The Q1 2025 earnings webcast will be archived and available for replay for 90 days following the event.

What diseases does INOVIO (INO) focus on treating?

INOVIO develops DNA medicines to treat and protect people from HPV-associated diseases, cancers, and infectious diseases.

Will analysts be able to ask questions during INOVIO's Q1 2025 earnings call?

Yes, while the event is listen-only, it will include a live Q&A session with analysts.